| Item Type | Name |
|
Concept
|
Antineoplastic Agents
|
|
Concept
|
Antineoplastic Agents, Alkylating
|
|
Concept
|
Antineoplastic Agents, Hormonal
|
|
Academic Article
|
Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis.
|
|
Academic Article
|
Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma.
|
|
Academic Article
|
Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone.
|
|
Academic Article
|
Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma.
|
|
Academic Article
|
Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
|
|
Academic Article
|
Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
|
|
Academic Article
|
Emerging drugs for chemotherapy-induced emesis.
|
|
Academic Article
|
Prevention of emesis from multiple-day and high-dose chemotherapy regimens.
|
|
Academic Article
|
Treatment of depressive symptoms in patients with early stage breast cancer undergoing adjuvant therapy.
|
|
Academic Article
|
Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting.
|
|
Academic Article
|
A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study.
|
|
Academic Article
|
Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
|
|
Academic Article
|
Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial.
|
|
Academic Article
|
A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study.
|
|
Academic Article
|
Palonosetron: a second generation 5-hydroxytryptamine 3 receptor antagonist.
|
|
Academic Article
|
Antiemetic control: toward a new standard of care for emetogenic chemotherapy.
|
|
Academic Article
|
Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: summary of clinical trials.
|
|
Academic Article
|
New approaches to chemotherapy-induced nausea and vomiting: from neuropharmacology to clinical investigations.
|
|
Academic Article
|
A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.
|
|
Academic Article
|
Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
|
|
Academic Article
|
Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments.
|
|
Academic Article
|
The current status of the use of palonosetron.
|
|
Academic Article
|
The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
|
|
Academic Article
|
Palonosetron for the treatment of chemotherapy-induced nausea and vomiting.
|
|
Academic Article
|
Clinical roundtable monograph: New data in emerging treatment options for chemotherapy-induced nausea and vomiting.
|
|
Academic Article
|
5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy.
|
|
Academic Article
|
Rolapitant for the treatment of chemotherapy-induced nausea and vomiting.
|
|
Academic Article
|
Treatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and Vomiting.
|
|
Academic Article
|
Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review.
|
|
Academic Article
|
The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting.
|
|
Academic Article
|
Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis.
|
|
Academic Article
|
Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting.
|
|
Academic Article
|
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.
|
|
Academic Article
|
Rolapitant hydrochloride: prophylactic treatment for chemotherapy-induced nausea and vomiting.
|
|
Academic Article
|
2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.
|
|
Academic Article
|
Olanzapine for Chemotherapy-Induced Nausea and Vomiting.
|
|
Academic Article
|
2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy.
|
|
Academic Article
|
Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients.
|
|
Academic Article
|
Managing Nausea and Vomiting in Patients With Cancer: What Works.
|
|
Academic Article
|
Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations.
|
|
Academic Article
|
Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis.
|
|
Academic Article
|
Safety of Polysorbate 80 in the Oncology Setting.
|
|
Academic Article
|
Do we still need to study palonosetron for chemotherapy-induced nausea and vomiting? A cumulative meta-analysis.
|
|
Academic Article
|
The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy.
|
|
Academic Article
|
Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review.
|
|
Academic Article
|
Unscheduled hydrations: redefining complete response in chemotherapy-induced nausea and vomiting studies.
|
|
Academic Article
|
Avoidable Acute Care Use Associated with Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin.
|
|
Academic Article
|
Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature.
|
|
Academic Article
|
Single-dose netupitant/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis.
|
|
Academic Article
|
Olanzapine 5 mg vs 10 mg for the prophylaxis of chemotherapy-induced nausea and vomiting: a network meta-analysis.
|
|
Academic Article
|
Duration of Chemotherapy-Induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles.
|
|
Academic Article
|
Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy.
|
|
Academic Article
|
Olanzapine With or Without Fosaprepitant for Preventing Chemotherapy Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial (ALLIANCE A221602).
|
|
Academic Article
|
Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
|
|
Academic Article
|
2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.
|